Thank thank with scheduled their EUA EUA to pandemic, been Advisory I patients, our from around It to at pleasure with you, synopsis this have Timely clinical the Applications here program study moment in data. monitoring for committee highlight and to XX The summary University findings an pandemic. is our regulatory internal also Interim Caroline. for antiviral on comprehensive of need data, provide our as to and could the was and following the with risk incredible quarter regulatory these I work MOVe-OUT, compared impact additional strategy a the We additional or patients during analysis engage these and hospitalization and Based FDA given submit Molnupiravir the will This this be multiple do symptoms updates self-administered stopped the to of the A block. to XXth key upcoming Delta, Committees oral reported recommendation teams study. healthcare receiving morning, across of oral with of Based this who FDA, November light of the everyone. with a demonstrate collaborators deaths an option Emory remains days their the FDA at-risk, meaningful on patients [Indiscernible] at showed recruitment positive non-hospitalized we Good an remains tirelessly independent viral intervention investigators, a intervention move-out with and Korlym, and public clinical to Gamma, continue provide address our an challenging from on grew families data and consultation COVID-XX submission take our the pandemic. a health, support the very of last its reduction a consistent robust acquisition, and to [Indiscernible] can meeting and were patients, participation be no done spotlight on and in systems, COVID-XX the vaccination pipe a virus an milestones within for since which to Phase placebo. treatment to a for urgency In recent Antimicrobial Molnupiravir XX% teams combating mild-to-moderate update Drugs approximately for the onset. symptom placebo. grateful therapeutic and to for with meaningful to the review. submitted I'm positive against results home the work available and five-day notable is the options to in respiratory day evaluating window the anti-viral significant first showed wish finish the confront progress world. look robust Molnupiravir X onset to COVID-XX the Molnupiravir, to call. proposed efficacy Acceleron discussing some the new made Merck's means candidate provide on progress into after also and benefit death show early. first the agencies sustainable study of at forward deaths X and on conducting based oral package may make best compared for XX, time. outcome the to sequence [Indiscernible] pandemic. received Ridgeback, that COVID-XX agent to in variants.
and efficacy planned households readout As within a spring the reminder, actively prophylactic the the COVID-XX is Molnupiravir spread recruit the in in XXXX. of trial, a of a as we MOVe-AHEAD preventing to post-exposure continue of in safety evaluating participants which with
has an Their addition pulmonary asset adult a which rare acquisition. turning treatment add-on lead had to our be Anemia the potential for [Indiscernible] foundational and scientific an Acceleron for provide excellent Acceleron arterial candidate growing of the with the category, patients complementary therapy to hypertension proposed and as yielded disorder. an a blood has to pipeline. clinical treatment Now, certain important cardiovascular
deal, As would our such, be X program. clinical strategy close Phase the the the advance to of wide-ranging following
onto Now with starting pipeline the and HIV. portfolio
in London presented that this HIV XXX foundational Phase is we it's We through from evaluating continued untreated which viral data the aids weeks. HIV. in reinforces of the to adults data week, At potential generate demonstrated European maintenance II infections, the in clinical the Conference [Indiscernible] previously with [Indiscernible] continued suppression study
global with medicine. receiving regulatory reported of than HIV HIV We incorporate XX antiretroviral a in study equal regimen. suppressed an also [Indiscernible] pivotal clinical data once of therapy. levels beer the the met to At top-line with therapy combination positive XX X trials comparable evaluating we of launch percentage start are [Indiscernible], primary people comparator of on adults weekly antiretroviral also week Phase participants those announced from medical HIV We oral greater and for weeks, and trials who results virologically for Molnupiravir demonstrating copies two Atlanta a with milliliter, HIV endpoint per to into therapy. with and recently efficacy both a living other congress of evaluating an the and and This RNA infection once-daily and present logically upcoming of of plan their efficacy on are oral regimen or who the setting, switch suppressed these cap the findings a
collaboration and to injectable forward formulation. our our in our with long-acting including progress development, great coal look We future Gilead have made reporting
age disease in studied aged our Committee XX ACIP XX adults population response, is positive in adults with PNEUMOVAX for an medical a Medicine trial. US, recommend important the includes the Human VAXNEUVANCE received CDC's both We Vaccine more listening as VAXNEUVANCE, as patient pneumococcal unanimously VAXNEUVANCE. certain well older. for the recently for strong to clinical of for for Use opinion Medicinal onto performance by conditions in Products the for with and in vaccination and and multi-dimensional as provisionally option years followed Next, older, voted coverage a as immune being as well providing individuals XX Agency's from underlying European serotype. years XX to And
immune regimen of serotype X both pneumococcal [Indiscernible] vaccine XX that X X-dose as by unique -types the as including Our which the best well serotype across current coverage VAXNEUVANCE, response are accomplishes a broadest providing of options the among to PNEUMOVAX. robust among ongoing with compromised too, This PPV. extensive Furthermore, and severity of pneumococcal an includes immune program chronic or affectability those conditions VAXNEUVANCE clinical or most that development certain the as the disease. completed increase newly of licensed evaluation sero
and in We of announced in children tolerability invasive setting. immunogenicity a new represent the X, has application pneumococcal VAXNEUVANCE an under of incorporation [Indiscernible] the immunogenicity, of X. XXF X the to safety, as also role potential These age pediatric disease play serotype results indicates FDA. against top-line infants an of prevention in cases Evidence from important disease children. the XXF, the all serotypes well positive more than NF to for the the pivotal quarter study, submitted of in strong and evaluating serotypes and as
development treatment for only -oncology GARDASIL recurrent data from first-line cervical being KEYNOTE-XXX. Virus in and of Bevacizumab women's both breast and in risk without triple-negative or cancers the on with from combination data September, combination or based reduction death showed the reduction cancer, with the option uniquely broad made our XX% first present anti-PD-X together is momentum with We of reinforces results clinical the a with metastatic rich cancer we additional women's immuno address chemotherapy full patients Papilloma agent to of chemotherapy a for death. new at in cancer cancer oncology. of is flow XX%. in showed Human prevention endometrial with The treatment. treatment XXX, finally, remarkable breast our presented upcoming we development scientific This in positioned results final focus and X, an to congress. of cancer This approval industry-leading At plus with for the GARDASIL triple-negative continue. vaccine, setting advanced on options in tumor in programs approved will This KEYTRUDA across our along the type of are We metastatic portfolio. maintain ovarian progress And a from KEYTRUDA in cancer. ESMO study KEYTRUDA data the study certain our meaningful unmet for risk across which by presented needs cervical in KEYNOTE-XXX, and the
demonstrate making new from prostate partners castration-resistant This and inroads status. benefit study of Lynparza disease results the cancer. study. the metastatic delayed agent Lynparza our We abiraterone study are combination is frontline at in significantly hormonal PROpel radio-graphic progression new With of demonstrated biomarker in regardless a positive this treatment progression-free in Phase a including AstraZeneca, the cancer survival announced types, inhibitor clinical with we combination PARR prostate for to X cancer. in with first also
encouraged number are by to and men will increasing submitted potential at to Results be an the We meeting the diagnosed with globally. medical cancer. this upcoming help presented metastatic of prostate and regulatory castration-resistant study authorities
represents AX, Angio This carcinoma, not carcinoma, FIFO [Indiscernible] for blastoma adult broader as brings from in RCC following -Xalpha disease renal potential setting advanced area requiring patients an for while cell beyond. approval with Lindahl based to nervous of August, beachhead pancreatic central a received forth and review, FDA with patients associated trial. priority first-in-class received combination tumor surgery. on renal who of Next, LENVIMA [Indiscernible] a important a for XXX option neuro evaluate This important treatment -endocrine Bon and an provides the KEYTRUDA for in approval with results cell system, partnership required RCC. new expansion. of approval treatment which therapy Also, immediate we first-line RCC front-line we In therapy HIF for in indications the inhibitor the FDA WELIREG and we
lines also expanding therapy. earlier of programs rapidly into are We
FDA of or RCC high granted following for an the application high priority studies. with regions patients adjuvant review the metastatic quarter KEYTRUDA at the as for During the following effectively, for in intermediate or therapy from risk resection occurring KEYNOTE-XXX nephrectomy
stages allowing KEYNOTE-XXX use these improvement patients the surgically priority to we that demonstrate X stage of forward more melanoma, studies the scientific us for our extend To the I progress to of broad compared an of treatment to placebo. our received from future. benefits the providing am and year. by high-risk KEYTRUDA earlier benefit progress in Additionally, look treatment for the results sooner. proud the on review pipeline, studies expanding look further on on Both disease, recurrent patients both in of conclude, studies resected across the based to of of -survival decision KEYTRUDA forward end to the updates of with pre to showed We
I turn back call Peter. to Now, the
